Kyverna jumps as rare muscle disorder cell therapy shows strong mid-stage results

Kyverna Therapeutics

22/04/2026 11:33

** Shares of biotech firm Kyverna Therapeutics KYTX.O jump 20.6% to $11.71 premarket

** Co says its experimental cell therapy miv-cel showed strong results in a mid-stage study for stiff person syndrome, a rare neurological disorder that causes severe muscle stiffness and painful spasms

** Co says a single dose led to rapid and lasting improvements in walking and mobility for most patients in the trial

** Says 81% of patients saw meaningful gains in walking speed, while about two-thirds no longer needed walking aids after 16 weeks

** Says all patients were able to stop immune-suppressing drugs, the current standard treatment that often provides limited relief

** Says the therapy was generally well tolerated, with some manageable side effects such as temporary low white blood cell counts

** As of last close, stock up ~3% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))